Piper Sandler price target $4.50Who does that two days before FDA PDUFA?
An analyst who looks at the LMNL / Kedrion deal that happened two weeks prior to FDA approval.
Sold two collection facilities for $17M, Ryplazim and plazma line for $5M. Gave 30% of the PRV for no consideration at all. Kedrion should get about $30M from the sale of PRV.
After reviewing this "deal", Piper gave it a somewhat high evaluation at $4.50. The share price needs to climb 12% in order to get to Piper's price. This during a time of falling LMNL price.